💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Large U.S. farm study finds no cancer link to Monsanto weedkiller

Published 11/09/2017, 10:46 AM
© Reuters. FILE PHOTO: Monsanto's research farm is pictured near Carman, Manitoba
MON
-

By Kate Kelland

LONDON, (Reuters) - A large long-term study on the use of the big-selling weedkiller glyphosate by agricultural workers in the United States has found no firm link between exposure to the pesticide and cancer, scientists said on Thursday.

Published in the Journal of the National Cancer Institute (JNCI), the study found there was no association between glyphosate, the main ingredient in Monsanto's popular herbicide RoundUp, "and any solid tumors or lymphoid malignancies overall, including non-Hogkin Lymphoma (NHL) and its subtypes".

It said there was "some evidence of increased risk of acute myeloid leukemia (AML) among the highest exposed group", but added this association was "not statistically significant".

The findings are likely to impact legal proceedings in the United States against Monsanto (NYSE:MON), in which more than 180 plaintiffs are claiming exposure to RoundUp gave them cancer - allegations that Monsanto denies.

The findings may also influence a crucial decision due by the end of the year on whether glyphosate should be re-licensed for sale across the European Union.

EU countries had been due to vote on the issue on Thursday, but again failed to agree to a proposal for a five-year extension.

The EU decision has been delayed for more than a year after the World Health Organization's International Agency for Research on Cancer (IARC) reviewed glyphosate in 2015 and concluded it was "probably carcinogenic" to humans. Other bodies, such as the European Food Safety Authority, have concluded glyphosate is safe to use.

The research is part of a large and important project known as the Agricultural Health Study (AHS), which has been tracking the health of tens of thousands of agricultural workers, farmers and their families in Iowa and North Carolina.

Since the early 1990s, it has gathered and analyzed detailed information on the health of participants and their families, and their use of pesticides, including glyphosate.

David Spiegelhalter, a professor of the Public Understanding of Risk at Britain's Cambridge University who has no link to the research, said Thursday's findings were from a "large and careful study" and showed "no significant relationship between glyphosate use and any cancer".

He added that the possible association with AML "is no more than one would expect by chance" and was not a concern.

Reuters reported in June how an influential scientist was aware of new AHS data while he was chairing a panel of experts reviewing evidence on glyphosate for the International Agency for Research on Cancer (IARC) in early 2015.

But since it had not at that time been published, he did not tell the expert panel about it and IARC's review did not take it into account.

The publication of the study on Thursday comes more than four years since drafts based on the AHS data on glyphosate and other pesticides were circulating in February and March 2013.

In a summary of the results, the researchers, led by Laura Beane Freeman, principal investigator of the AHS at the U.S. National Cancer Institute, said that among 54,251 (pesticide) applicators studied, 44,932, or 82.9 percent, used glyphosate.

"Glyphosate was not statistically significantly associated with cancer at any site," the summary said.

Scott Partridge, Monsanto's vice president of strategy, said the study results clearly showed the weedkiller was safe.

© Reuters. FILE PHOTO: Monsanto's research farm is pictured near Carman, Manitoba

"This is the largest study of agricultural workers in history, over the longest period of time," he told Reuters. "It is the gold standard,... and it definitively demonstrates in a real-world environment that glyphosate doesn't cause cancer."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.